Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2026 | Emerging treatments for MS: BTK inhibitors, monoclonal antibodies, and CAR T-cells

Patricia Coyle • 20 Apr 2026
AAN 2026
Multiple Sclerosis and Related Disorders Antibodies BTK inhibitors CAR-T Frexalimab Obexelimab Remibrutinib
MoonStone

Patricia Coyle, MD, Stony Brook Medicine, Lake Grove, NY, discusses several emerging treatments for multiple sclerosis (MS), including BTK inhibitors, monoclonal antibodies, and CAR T-cells. This interview took place at the 78th American Academy of Neurology (AAN) Annual Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Patricia Coyle

Efficacy of tolebrutinib in non-relapsing and relapsing MS: insights from pivotal Phase III trials
1:42
Efficacy of tolebrutinib in non-relapsing and relapsing MS: insights from pivotal Phase III trials
Patricia Coyle • 20 Apr 2026
Tolebrutinib in a North American cohort with NRSPMS: subgroup analysis of HERCULES
2:05
Tolebrutinib in a North American cohort with NRSPMS: subgroup analysis of HERCULES
Patricia Coyle • 20 Apr 2026

Related Videos

Aerobic training and its potential impact on neurogenesis in progressive multiple sclerosis
4:05
Aerobic training and its potential impact on neurogenesis in progressive multiple sclerosis
Tetsu Morozumi • 29 Apr 2026
Baseline characteristics to predict response to aerobic training and physical rehabilitation in MS
4:12
Baseline characteristics to predict response to aerobic training and physical rehabilitation in MS
Tetsu Morozumi • 19 Apr 2026
Phase II open-label extension of frexalimab in participants with relapsing multiple sclerosis
6:10
Phase II open-label extension of frexalimab in participants with relapsing multiple sclerosis
Patrick Vermersch • 24 Apr 2026
A digital tool to detect disability worsening in multiple sclerosis: the MS-DETECT study
4:36
A digital tool to detect disability worsening in multiple sclerosis: the MS-DETECT study
Patrick Vermersch • 24 Apr 2026
The content of VJNeurology is intended for healthcare professionals